Replies to post #1804 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

…given so-so results in RSV and HBV (if recollection serves).

ENTA hasn’t yet had any clinical results in HBV.

In RSV, there isn’t any competition for a treatment (rather than a vaccine), so even a “so-so” drug in an absolute sense could be a big commercial success.

In short, ENTA’s pipeline definitely has value.